All In MedTech

Device Trial Radar · NCT06272981

A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH™ SF Catheter With the TRUPULSE™ Generator for Treatment of Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation (PAF)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

136

Actual

Start

Feb 28, 2024

Primary completion

Oct 28, 2025

Study completion Oct 28, 2025

Sponsor

Lead sponsor
Biosense Webster, Inc.Public (JNJ)
Sponsor type
Industry
First posted
Feb 22, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow \[STSF\] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.

Conditions

  • Atrial Fibrillation

Interventions

  • Pulsed Field (PF) /Radiofrequency (RF) Catheter ablationDevice

    THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Primary Adverse Events (PAEs)Time frame: Up to 12 Months post ablation procedure on Day 0
  2. Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure ModesTime frame: From Day 91 up to Day 365 post ablation procedure on Day 0

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • Canberra Heart Rhythm

    Garran, Australia

  • Westmead Hospital

    Westmead, Australia

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.